RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-16 17:52 | 2026-09-15 | RXRX | Taylor Ben R | CFO | F - Tax | $3.41 | -5,396 | 1.07M | -0.5% | -$18.4K | |
| T | 2026-09-10 17:55 | 2026-09-08 | RXRX | Khan Najat | CEO, Pres, Dir | S - Sale | $3.52 | -22.4K | 2.07M | -1% | -$78.8K |
| T | 2026-09-02 18:01 | 2026-09-01 | RXRX | Borgeson Blake | Dir | S - Sale | $3.34 | -30.0K | 6.16M | -0.5% | -$100.2K |
| 2026-08-18 17:44 | 2026-08-17 | RXRX | Khan Najat | CEO, Pres, Dir | F - Tax | $3.16 | -80.5K | 2.10M | -4% | -$254.4K | |
| 2026-08-18 17:44 | 2026-08-17 | RXRX | Hallett David | CSO | F - Tax | $3.16 | -26.7K | 1.04M | -2% | -$84.2K | |
| 2026-08-18 17:44 | 2026-08-17 | RXRX | Taylor Ben R | CFO | F - Tax | $3.16 | -25.0K | 1.08M | -2% | -$79.1K | |
| T | 2026-08-06 17:09 | 2026-08-04 | RXRX | Borgeson Blake | Dir | S - Sale | $3.25 | -30.0K | 6.19M | -0.5% | -$97.5K |
| T | 2026-07-09 18:04 | 2026-07-07 | RXRX | Borgeson Blake | Dir | S - Sale | $3.96 | -40.0K | 6.22M | -0.6% | -$158.5K |
| 2026-07-02 17:15 | 2026-07-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +5,109 | 240.8K | +2% | $0 | |
| 2026-07-02 17:15 | 2026-07-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +3,747 | 1.47M | +0.3% | $0 | |
| 2026-06-22 16:32 | 2026-06-17 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +88.4K | 6.26M | +1% | $0 | |
| 2026-06-22 16:32 | 2026-06-17 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +88.4K | 162.2K | +120% | $0 | |
| 2026-06-22 16:32 | 2026-06-17 | RXRX | Michor Franziska | Dir | A - Grant | $0.00 | +88.4K | 215.5K | +70% | $0 | |
| 2026-06-22 16:32 | 2026-06-17 | RXRX | Sun Elaine D | Dir | A - Grant | $0.00 | +88.4K | 136.0K | +186% | $0 | |
| 2026-06-22 16:32 | 2026-06-17 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +88.4K | 235.7K | +60% | $0 | |
| 2026-06-22 16:32 | 2026-06-17 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +88.4K | 1.47M | +6% | $0 | |
| T | 2026-06-22 16:32 | 2026-06-17 | RXRX | Bumpus Namandje | Dir | A - Grant | $0.00 | +88.4K | 131.6K | +205% | $0 |
| T | 2026-06-22 16:32 | 2026-06-18 | RXRX | Bumpus Namandje | Dir | S - Sale | $3.18 | -3,963 | 127.6K | -3% | -$12.6K |
| 2026-06-17 17:07 | 2026-06-15 | RXRX | Taylor Ben R | CFO | F - Tax | $3.15 | -5,396 | 1.10M | -0.5% | -$17.0K | |
| DT | 2026-06-05 17:03 | 2026-06-05 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 923.7K | +5% | $0 |
| DT | 2026-06-05 17:03 | 2026-06-05 | RXRX | Gibson Christopher | Dir | S - Sale | $3.62 | -40.0K | 883.7K | -4% | -$144.8K |
| T | 2026-06-05 17:02 | 2026-06-05 | RXRX | Khan Najat | CEO, Pres, Dir | S - Sale | $3.58 | -23.6K | 2.18M | -1% | -$84.5K |
| T | 2026-06-04 17:04 | 2026-06-03 | RXRX | Bumpus Namandje | Dir | S - Sale | $3.54 | -4,386 | 43.2K | -9% | -$15.5K |
| T | 2026-06-04 17:04 | 2026-06-02 | RXRX | Borgeson Blake | Dir | S - Sale | $3.68 | -30.0K | 6.17M | -0.5% | -$110.4K |
| DT | 2026-05-27 16:15 | 2026-05-22 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 923.7K | +5% | $0 |
| DT | 2026-05-27 16:15 | 2026-05-22 | RXRX | Gibson Christopher | Dir | S - Sale | $3.08 | -40.0K | 883.7K | -4% | -$123.2K |
| 2026-05-19 17:54 | 2026-05-15 | RXRX | Hallett David | CSO | F - Tax | $3.04 | -26.7K | 1.07M | -2% | -$81.0K | |
| 2026-05-19 17:54 | 2026-05-15 | RXRX | Khan Najat | CEO, Pres, Dir | F - Tax | $3.04 | -62.7K | 2.20M | -3% | -$190.6K | |
| 2026-05-19 17:54 | 2026-05-15 | RXRX | Taylor Ben R | CFO | F - Tax | $3.04 | -25.0K | 1.11M | -2% | -$76.1K | |
| 2026-05-19 17:54 | 2026-05-15 | RXRX | Gibson Christopher | Dir | F - Tax | $3.04 | -22.8K | 883.7K | -3% | -$69.4K | |
| DT | 2026-05-08 16:59 | 2026-05-07 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +60.0K | 966.6K | +7% | $0 |
| DT | 2026-05-08 16:59 | 2026-05-07 | RXRX | Gibson Christopher | Dir | S - Sale | $3.37 | -40.0K | 926.6K | -4% | -$134.8K |
| DT | 2026-05-08 16:59 | 2026-05-07 | RXRX | Gibson Christopher | Dir | G - Gift | $0.00 | -20.0K | 906.6K | -2% | $0 |
| T | 2026-05-07 16:44 | 2026-05-05 | RXRX | Borgeson Blake | Dir | S - Sale | $3.52 | -30.0K | 6.20M | -0.5% | -$105.6K |
| DT | 2026-04-24 16:23 | 2026-04-22 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| DT | 2026-04-24 16:23 | 2026-04-22 | RXRX | Gibson Christopher | Dir | S - Sale | $3.61 | -40.0K | 906.6K | -4% | -$144.4K |
| 2026-04-08 16:58 | 2026-04-06 | RXRX | Taylor Ben R | CFO | F - Tax | $3.11 | -48.0K | 1.13M | -4% | -$149.4K | |
| DT | 2026-04-08 16:58 | 2026-04-07 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| DT | 2026-04-08 16:58 | 2026-04-07 | RXRX | Gibson Christopher | Dir | S - Sale | $3.10 | -40.0K | 906.6K | -4% | -$124.0K |
| T | 2026-04-08 16:58 | 2026-04-07 | RXRX | Borgeson Blake | Dir | S - Sale | $3.10 | -30.0K | 6.23M | -0.5% | -$93.0K |
| 2026-04-02 16:56 | 2026-04-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +4,902 | 147.2K | +3% | $0 | |
| 2026-04-02 16:56 | 2026-04-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +3,268 | 1.24M | +0.3% | $0 | |
| D | 2026-03-25 | 2026-03-23 | RXRX | Gibson Christopher | Dir | S - Sale | $3.25 | -40.0K | 906.6K | -4% | -$130.0K |
| D | 2026-03-25 | 2026-03-23 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| 2026-03-18 | 2026-03-17 | RXRX | Taylor Ben R | CFO | S - Sale | $3.39 | -7,956 | 1.18M | -0.7% | -$27.0K | |
| 2026-03-18 | 2026-03-16 | RXRX | Taylor Ben R | CFO | F - Tax | $3.42 | -7,075 | 1.19M | -0.6% | -$24.2K | |
| 2026-03-11 | 2026-03-09 | RXRX | Khan Najat | CEO, Pres, Dir | S - Sale | $3.35 | -28.3K | 2.26M | -1% | -$94.8K | |
| D | 2026-03-11 | 2026-03-09 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +20.0K | 926.6K | +2% | $0 |
| D | 2026-03-11 | 2026-03-09 | RXRX | Gibson Christopher | Dir | G - Gift | $0.00 | -20.0K | 906.6K | -2% | $0 |
| 2026-03-04 | 2026-03-03 | RXRX | Borgeson Blake | Dir | S - Sale | $3.46 | -170.0K | 6.26M | -3% | -$588.2K | |
| 2026-02-19 | 2026-02-17 | RXRX | Taylor Ben R | CFO | F - Tax | $3.49 | -11.9K | 1.21M | -1.0% | -$41.6K | |
| 2026-02-19 | 2026-02-18 | RXRX | Taylor Ben R | CFO | S - Sale | $3.08 | -13.4K | 1.20M | -1% | -$41.4K | |
| 2026-02-19 | 2026-02-17 | RXRX | Hallett David | CSO | F - Tax | $3.49 | -11.9K | 1.10M | -1% | -$41.6K | |
| D | 2026-02-19 | 2026-02-19 | RXRX | Gibson Christopher | Dir | S - Sale | $3.46 | -40.0K | 906.6K | -4% | -$138.4K |
| D | 2026-02-19 | 2026-02-19 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| D | 2026-02-19 | 2026-02-17 | RXRX | Gibson Christopher | Dir | F - Tax | $3.49 | -27.3K | 906.6K | -3% | -$95.2K |
| 2026-02-19 | 2026-02-17 | RXRX | Khan Najat | CEO, Pres, Dir | F - Tax | $3.49 | -14.3K | 2.29M | -0.6% | -$49.8K | |
| M | 2026-02-10 | 2026-02-06 | RXRX | Taylor Ben R | CFO | A - Grant | $0.00 | +470.5K | 1.23M | +62% | $0 |
| 2026-02-10 | 2026-02-06 | RXRX | Taylor Ben R | CFO | F - Tax | $3.98 | -11.4K | 1.22M | -0.9% | -$45.4K | |
| M | 2026-02-10 | 2026-02-06 | RXRX | Hallett David | CSO | A - Grant | $0.00 | +526.3K | 1.10M | +92% | $0 |
| 2026-02-10 | 2026-02-06 | RXRX | Hallett David | CSO | F - Tax | $3.98 | -11.4K | 1.11M | -1% | -$45.4K | |
| M | 2026-02-10 | 2026-02-06 | RXRX | Khan Najat | CEO, Pres, Dir | A - Grant | $0.00 | +1.70M | 2.28M | +293% | $0 |
| 2026-02-10 | 2026-02-06 | RXRX | Khan Najat | CEO, Pres, Dir | F - Tax | $3.98 | -10.4K | 2.30M | -0.4% | -$41.2K | |
| D | 2026-02-06 | 2026-02-04 | RXRX | Gibson Christopher | Dir | S - Sale | $4.12 | -40.0K | 913.8K | -4% | -$164.8K |
| D | 2026-02-06 | 2026-02-06 | RXRX | Gibson Christopher | Dir | A - Grant | $0.00 | +30.3K | 944.2K | +3% | $0 |
| D | 2026-02-06 | 2026-02-06 | RXRX | Gibson Christopher | Dir | F - Tax | $3.56 | -10.4K | 933.8K | -1% | -$36.9K |
| D | 2026-02-06 | 2026-02-04 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| 2026-02-06 | 2026-02-03 | RXRX | Borgeson Blake | Dir | S - Sale | $4.20 | -220.0K | 6.43M | -3% | -$924.0K | |
| D | 2026-01-22 | 2026-01-20 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| D | 2026-01-22 | 2026-01-20 | RXRX | Gibson Christopher | Dir | S - Sale | $4.47 | -40.0K | 913.8K | -4% | -$178.8K |
| 2026-01-08 | 2026-01-06 | RXRX | Borgeson Blake | Dir | S - Sale | $4.36 | -220.0K | 6.65M | -3% | -$959.2K | |
| D | 2026-01-07 | 2026-01-05 | RXRX | Gibson Christopher | Dir | S - Sale | $4.25 | -40.0K | 933.8K | -4% | -$170.0K |
| D | 2026-01-07 | 2026-01-05 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +60.0K | 973.8K | +7% | $0 |
| D | 2026-01-07 | 2026-01-05 | RXRX | Gibson Christopher | Dir | G - Gift | $0.00 | -20.0K | 913.8K | -2% | $0 |
| 2026-01-06 | 2026-01-02 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +3,571 | 142.3K | +3% | $0 | |
| 2026-01-06 | 2026-01-02 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +2,381 | 1.24M | +0.2% | $0 | |
| 2025-12-30 | 2025-12-29 | RXRX | Taylor Ben R | CFO | S - Sale | $4.18 | -21.4K | 761.5K | -3% | -$89.4K | |
| 2025-12-29 | 2025-12-22 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | S - Sale | $4.41 | -124.4K | 611.1K | -17% | -$548.6K | |
| D | 2025-12-19 | 2025-12-19 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $4.50 | -40.0K | 913.8K | -4% | -$180.0K |
| D | 2025-12-19 | 2025-12-19 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| 2025-12-17 | 2025-12-15 | RXRX | Taylor Ben R | CFO | F - Tax | $4.33 | -7,057 | 782.9K | -0.9% | -$30.6K | |
| D | 2025-12-05 | 2025-12-04 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +60.0K | 973.8K | +7% | $0 |
| D | 2025-12-05 | 2025-12-04 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 913.8K | -2% | $0 |
| D | 2025-12-05 | 2025-12-04 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $4.63 | -40.0K | 933.8K | -4% | -$185.2K |
| 2025-12-04 | 2025-12-02 | RXRX | Borgeson Blake | Dir | S - Sale | $4.37 | -220.0K | 6.87M | -3% | -$961.4K | |
| 2025-11-26 | 2025-11-25 | RXRX | Taylor Ben R | CFO | F - Tax | $4.03 | -2,271 | 790.0K | -0.3% | -$9,152 | |
| 2025-11-19 | 2025-11-17 | RXRX | Taylor Ben R | CFO | F - Tax | $4.14 | -11.9K | 792.3K | -1% | -$49.3K | |
| D | 2025-11-19 | 2025-11-17 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $4.14 | -40.4K | 913.8K | -4% | -$167.2K |
| D | 2025-11-19 | 2025-11-19 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $4.16 | -40.0K | 913.8K | -4% | -$166.4K |
| D | 2025-11-19 | 2025-11-19 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| 2025-11-19 | 2025-11-17 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $4.14 | -17.6K | 735.5K | -2% | -$72.8K | |
| D | 2025-11-06 | 2025-11-05 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +84.9K | 753.1K | +13% | $0 |
| D | 2025-11-06 | 2025-11-04 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $5.21 | -40.0K | 974.2K | -4% | -$208.4K |
| D | 2025-11-06 | 2025-11-04 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +60.0K | 1.01M | +6% | $0 |
| D | 2025-11-06 | 2025-11-04 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 954.2K | -2% | $0 |
| D | 2025-10-24 | 2025-10-23 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 1.05M | +10% | $0 |
| D | 2025-10-24 | 2025-10-23 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $5.70 | -100.0K | 954.2K | -9% | -$570.0K |
| D | 2025-10-10 | 2025-10-10 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 954.2K | -2% | $0 |
| D | 2025-10-10 | 2025-10-10 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +120.0K | 1.07M | +13% | $0 |
| D | 2025-10-10 | 2025-10-10 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $6.04 | -100.0K | 974.2K | -9% | -$604.0K |
Purchase Sale Sale after option exercise All abbreviations